9 4 3 6 4
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
贝伐单抗 (Bevacizumab) 与顺铂 (cisplatin) 和螺旋断层放疗相结合治疗局部晚期鼻咽癌
Authors Li JX, Zhao ZF, Wu X, Yao J, Ma L, Ye R, Niu BL, Liang LQ, Zhao X, Wang QQ
Published Date June 2015 Volume 2015:8 Pages 1315—1319
DOI http://dx.doi.org/10.2147/OTT.S80159
Received 1 January 2015, Accepted 10 March 2015, Published 2 June 2015
Approved for publication by Dr William C Cho
Background: In recent years, chemotherapy, radiotherapy, and targeted drugs have been respectively used in nasopharyngeal carcinoma. In our research, we combined all of them for better curative effects.
Materials and methods: Thirty patients with histologically confirmed stage III~IV (without distant metastasis) nasopharyngeal carcinoma were recruited between December 2013 and October 2014 with strict eligibility requirements and exclusion criteria. Bevacizumab 5 mg/kg, 80 mg/m2 cisplatin and 67.5 Gy radiotherapy (helical tomotherapy [TOMO]) was given according to standard treatment protocols.
Results: After 3 months, 24 complete responses (80%) and six partial responses (40%) were observed in our research. Twenty-four patients (80%) experienced oropharyngeal mucositis, 26% patients experienced weight loss caused by pharyngeal pain and dysphagia caused by oropharyngeal mucositis.
Conclusion: Bevacizumab plus cisplatin and TOMO in treatment of locally advanced nasopharyngeal carcinoma can increase curative effects with low side effects and toxicities.
Keywords: bevacizumab, cisplatin, helical tomotherapy (TOMO), nasopharyngeal carcinoma
Materials and methods: Thirty patients with histologically confirmed stage III~IV (without distant metastasis) nasopharyngeal carcinoma were recruited between December 2013 and October 2014 with strict eligibility requirements and exclusion criteria. Bevacizumab 5 mg/kg, 80 mg/m2 cisplatin and 67.5 Gy radiotherapy (helical tomotherapy [TOMO]) was given according to standard treatment protocols.
Results: After 3 months, 24 complete responses (80%) and six partial responses (40%) were observed in our research. Twenty-four patients (80%) experienced oropharyngeal mucositis, 26% patients experienced weight loss caused by pharyngeal pain and dysphagia caused by oropharyngeal mucositis.
Conclusion: Bevacizumab plus cisplatin and TOMO in treatment of locally advanced nasopharyngeal carcinoma can increase curative effects with low side effects and toxicities.
Keywords: bevacizumab, cisplatin, helical tomotherapy (TOMO), nasopharyngeal carcinoma
